secwatch.observer — SEC 8-K summary
======================================

Issuer:     Instil Bio, Inc. (TIL)
CIK:        0001789769
Form:       8-K
Filed at:   2026-08-13T20:59:21+00:00
Accession:  0001789769-26-000055
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Instil Bio Q2 2026 net loss $0.63/share; cash $69.9M funds beyond 2027
----------------------------------------------------------------------

- Cash, equivalents, restricted cash and marketable securities $69.9M at June 30, 2026, down from $76.3M at Dec 31, 2025.
- Q2 2026 net loss per share $0.63 (basic/diluted) vs $3.24 in Q2 2025; non-GAAP $0.45 vs $2.88.
- R&D expenses $0.3M in Q2 2026 vs $6.7M in Q2 2025; G&A $5.1M vs $6.2M.
- In-process R&D expenses nil vs $10.0M in Q2 2025; restructuring charges $0.2M vs $0.5M.
- Company evaluating potential acquisitions, in-licensing opportunities for novel therapeutic candidates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789769/000178976926000055/0001789769-26-000055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789769/000178976926000055/til-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001789769-26-000055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer